The unique features of pediatric HIV-1 in sub-Saharan Africa

Current HIV Research

Volumn 6, Issue 4, 2008, Pages 351-362

  De Baets, Anniek J ^a   Ramet, Jose ^a   Msellati, Philippe ^b   Lepage, Philippe ^c  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b AIX MARSEILLE UNIVERSITY   (France)

^c HOP UNIV DES ENFANTS REINE FABIOLA   (Belgium)

Author keywords

Africa; Antiretroviral therapy; ART outcome; Comparison; Features; Pediatric HIV

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE;

AFRICA; AFRICA SOUTH OF THE SAHARA; CD4+ T LYMPHOCYTE; CHILD; CHILD HEALTH CARE; CHILDHOOD MORTALITY; CLINICAL FEATURE; DELAYED DIAGNOSIS; DIAGNOSTIC PROCEDURE; DISEASE COURSE; DRUG HYPERSENSITIVITY; ENVIRONMENTAL FACTOR; EXPECTATION; FOLLOW UP; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HEALTH CARE QUALITY; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; LYMPHOCYTE COUNT; MEDLINE; PATIENT ATTITUDE; PATIENT COMPLIANCE; PHLEBOTOMY; POVERTY; REVIEW; SURVIVAL RATE; TREATMENT DURATION; TREATMENT OUTCOME; UNITED KINGDOM; UNITED STATES; UNSPECIFIED SIDE EFFECT; VERTICAL TRANSMISSION; VIROLOGY; VIRUS LOAD;

ADOLESCENT; ADULT; AFRICA SOUTH OF THE SAHARA; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; DEVELOPED COUNTRIES; DRUG ADMINISTRATION SCHEDULE; HIV INFECTIONS; HIV-1; HUMANS; INFANT; PEDIATRICS; PROGRAM EVALUATION; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 52449111345     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016208785132491     Document Type: Review

References (98)

1. Joint United Nations programme on HIV/AIDS. Report on the global AIDS epidemic. 2006. Geneva, Switzerland.
2. World Health Organization. Antiretroviral therapy of HIV infection in infants and children in resource-limited settings, towards universal access: recommendations for a public health approach (2006 revision). Geneva, Switzerland.
3. Meyers T, Moultrie H, Naidoo K, Cotton M, Eley B, Sherman G. Challenges to pediatric HIV care and treatment in South Africa. J Infect Dis 2007; 196: S474-S481.
4. Prendergast A, Tudor-Williams G, Jeena P, Burchett S, Goulder P. International perspectives, progress, and future challenges of paediatric HIV infection. Lancet 2007; 370: 68-80.
5. Arrivé E, Kyabayinze DJ, Marquis B, et al. Cohort profile: the Paediatric Antiretroviral Treatment Programmes in Lower-Income Countries (KIDS-ART-LINC) Collaboration. Int J Epidemiol 2008; 37: 474-80.
6. Kline MW. Perspectives on the pediatric HIV/AIDS pandemic: catalyzing access of children to care and treatment. Pediatrics 2006; 117: 1388-93.
7. Little K, Newell ML, Luo C, Ngongo N, Borja MC, McDermott P. Estimating the number of vertically HIV-infected children eligible for antiretroviral treatment in resource-limited settings. Int J Epidemiol 2007; 36: 679-87.
8. Newell ML, Coovadia H, Cortina-Borja M, Rollins NC, Gaillard P, Dabis F. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet 2004; 364: 1236-43.
9. Fowler MG, Mofenson L, McConnell M. The interface of perinatal HIV prevention, antiretroviral drug resistance, and antiretroviral treatment: what do we really know? J Acquir Immune Defic Syndr 2003; 34: 308-11.
10. Bulterys M, Weidle PJ, Abrams EA, Fowler MG. Combination antiretroviral therapy in African nursing mothers and drug exposure in their infants: new pharmacokinetic and virologic findings. J Infect Dis 2005; 192: 709-12.
11. Mphatswe W, Blanckenberg N, Tudor-Williams G, et al. High frequency of rapid immunological progression in African infants infected in the era of perinatal HIV prophylaxis. AIDS 2007; 21: 1253-61.
12. Dray-Spira R, Lepage P, Dabis F. Prevention of infectious complications of paediatric HIV infection in Africa. AIDS 2000; 14: 1091-9.
13. de Martino M, Tovo PA, Balducci M, et al. Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. JAMA 200; 284: 190-7.
14. Jones G, Steketee RW, Black RE, et al. How many child deaths can we prevent this year? Lancet 2003; 362: 65-71.
15. Ssewanyana I, Elrefaci M, Dorsey G, et al. Profile of T-cell immune responses in HIV-infected children from Uganda. J Infect Dis 2007; 196: 1667-70.
16. Nyandiko WM, Ayaya S, Nabakwe E, et al. Outcomes of HIV-infected orphaned and non-orphaned children on antiretroviral therapy in Western Kenya. J Acquir Immune Defic Syndr 2006; 43: 418-25.
17. Blè C, Floridia M, Muhale C, et al. Efficacy of highly active antiretroviral therapy in HIV-infected institutionalized orphaned children in Tanzania. Acta Paediatr 2007; 96: 1090-4.
18. De Baets AJ, Sifovo S, Parsons R, Pazvakavambwa IE. HIV disclosure and discussions about grief with Shona children: a comparison between health care workers and community members in Eastern Zimbabwe. Soc Sci Med 2007; 66: 479-91.
19. Van Damme W, Kober K, Laga M. The real challenges for scaling up ART in sub-Saharan Africa. AIDS 2006; 20: 653-6.
20. Ginsberg AS, Miller A, Wilfert CM. Diagnosis of pediatric human immunodeficiency virus infection in resource-constrained settings. Pediatric Infect Dis J 2006; 25: 1057-64.
21. Sharland M, Blanche S, Castelli G, Ramos J, Gibb D. PENTA guidelines for the use of antiretroviral therapy. HIV Med 2004; 5: 61-86.
22. Taha TE, Graham SM, Kumwenda NI, et al. Morbidity among human immunodeficiency virus-1-infected and -uninfected African children. Pediatrics 2000; 106: 1-8.
23. Barnhart HX, Caldwell MB, Thomas P, et al. Natural history of human immunodeficiency virus disease in perinatally infected children: an analysis from the Pediatric Spectrum of Disease Project. Pediatrics 1996; 97: 710-6.
24. Crowe S, Turnbull S, Oelrichs R, Dunne A. Montoring of human immunodeficiency virus infection in resource-constrained countries. Clin Infect Dis 2003; 37: S25-S35.
25. Goulder P Jr, Jeena P, Tudor-Williams G, Burchett S. Paediatric HIV infection: correlates of protective immunity and global perspectives in prevention and management. Br Med Bull 2001; 58: 89-108.
26. Madhi SA, Petersen K, Madhi A, Wasas A, Klugman KP. Impact of human immunodeficiency virus type 1 on the disease spectrum of Streptococcus pneumoniae in South African children. Pediatr Infect Dis J 2000; 19: 1141-7.
27. Van Rie A, Harrington PR, Dow A, Robertson K. Neurologic and neurodevelopmental manifestations of pediatric HIV/AIDS: a global perspective. Eur J Paediatr Neurol 2007; 11: 1-9.
28. Boivin MJ, Green SDR, Davies AG, Giordani B, Mokili JK, Cutting WA. A preliminary evaluation of the cognitive and motor effects of pediatric HIV infection in Zairian children. Health Psychol 1995; 14: 13-21.
29. Msellati P, Lepage P, Hitimana DG, Van Goethem C, Van de Perre P, Dabis F. Neurodevelopmental testing of children born to human immunodeficiency virus type 1 seropositive and seronegative mothers: a prospective cohort study in Kigali, Rwanda. Pediatrics 1993; 92: 843-8.
30. Faye A, Le Chenadec J, Dollfus C, et al. Early vs deferred antiretroviral mulidrug therapy in infants infected with HIV type 1. Clin Infect Dis 2004; 39: 1692-8.
31. Ghaffari G, Passalacqua DJ, Caicedo JL, Godenow MM, Sleasman JW. Two-year clinical and immune outcomes in human immunodeficiency virus-infected children who reconsitute CD4 T cells without control of viral replication after combination antiretroviral therapy. Pediatrics 2004; 114: e604-11.
32. van Kooten Niekerk NKM, Knies MM, Howard J, et al. The first 5 years of the family clinic for HIV at Tygerberg Hospital: family demographics, survival of children and early impact of antiretroviral therapy. J Trop Pediatr 2006; 52: 3-11.
33. Mwamburi DM, Wilson IB, Jacobson DL, et al. Understanding the role of HIV load in determining weight change in the era of highly active antiretroviral therapy. Clin Infect Dis 2005; 40: 167-73.
34. Guillén S, Ramos TJ, Resino R, Bellon JM, Munoz MA. Impact on weight and height with the use of HAART in HIV-infected children. Ped Infect Dis J 2007; 26: 334-8.
35. Bolton-Moore C, Mubiana-Mbewe M, Cantrell RA, et al. Clinical outcomes and CD4 cell response in children receiving antiretroviral therapy at primary health care facilities in Zambia. JAMA 2007; 298: 1888-9.
36. Wools-Kaloustian K, Kimaiyo S, Diero L, et al. Viability and effectiveness of large-scale HIV treatment initiatives in sub-Saharan Africa: experience from Western Kenya. AIDS 2006; 20: 41-8.
37. Paediatric European Network for Treatment of AIDS. HIV-1 viral load and CD4 cell count in untreated children with vertically acquired asymptomatic or mild disease. AIDS 1998; 12: F1-F8.
38. Song R, Jelagat J, Dzombo D, et al. Efficacy of highly active antiretroviral therapy in HIV-1 infected children in Kenya. Pediatrics 2007; 120: e856-e861.
39. Resino S, Resino R, Micheloud D, et al. Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type-1 infected children: 6 years of follow-up. Clin Infect Dis 2006; 42: 862-9.
40. Laurent C, Diakhaté N, Gueye NFN, et al. The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up study. AIDS 2002; 16: 1363-70.
41. Coetzee D, Hildebrand K, Boulle A, et al. Outcomes after two years of providing antiretroviral treatment in Kayelitsha, South Africa. AIDS 2004; 18: 887-95.
42. The Antriretroviral Therapy in Lower Income Countries Collaboration and ART Cohort Collaboration Groups. Mortality of HIV-1 infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006; 367: 817-24.
43. Vigan A, Vella S, Saresella M, et al. Early immune reconstitution after potent antiretroviral therapy in HIV-infected children correlates with the increase in thymus volume. AIDS 2000; 14: 251-61.
44. van Rossum AMC, Fraaij PLA, de Groot R. Efficacy of highly active antiretroviral therpay in HIV-1 infected children. Lancet Inf Dis 2002; 2: 93-102.
45. Walker SA, Doerholt K, Sharland M, Gibb D. Response to highly active antiretroviral therapy varies with age: the UK and Ireland Collaborative HIV Paediatric Study. AIDS 2004; 18: 1915-24.
46. O'Brien DP, Sauvageot D, Olson D, et al. Treatment outcomes stratified by baseline immunological status among young children receiving nonnucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in resource-limited settings. Clin Infect Dis 2007; 44: 1245-8.
47. Soh CH, Oleske JM, Brady MT, et al. Long-term effects of protease-inhibitor-based combination therapy on CD4 T-cell recovery in HIV-1-infected children and adolescents. Lancet 2003; 362: 2045-51.
48. Saez-Llorens X, Violari A, Deetz CO, et al. Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2003; 22: 216-23.
49. Wamalwa DC, Farquhar C, Obimbo EM, et al. Early response to highly active antiretroviral therapy in HIV-1-infected Kenyan children. J Acquir Immune Defic Syndr 2007; 45: 311-7.
50. Rouet F, Fassinou P, Inwoley A, et al. Long-term survival and immuno-virological response of African HIV-1-infected children to highly active antiretroviral therapy regimens. AIDS 2006; 20: 2315-9.
51. Paediatric European Network for Treatment of AIDS. Highly active antiretroviral therapy started in infants under 3 months of age: 72-week follow-up for CD4 cell count, viral load and drug resistance outcome. AIDS 2004; 18: 237-45.
52. Weidle PJ, Malamba S, Mwebaze R, et al. Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance. Lancet 2002; 360: 34-40.
53. Starr SE, Fletcher CV, Spector SA, et al. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. N Engl J Med 1999; 341: 1874-81.
54. Delaugerre C, Teglas JP, Tréluyer JM, et al. Predictive Factors of virologic success in HIV-1-infected children treated with lopinavir/ritonavir. J Acquir Immune Defic Syndr 2004; 37: 1269-75.
55. The Malawi Paediatric Antiretroviral Treatment Group. Antiretroviral therapy for children in the routine setting in Malawi. Trans Roy Soc Trop Med Hyg 2007; 101: 511-6.
56. Karcher H, Omondi A, Odera J, Kunz A, Harms G. Risk factors for treatment denial and loss to follow-up in antiretroviral treatment cohort in Kenya. Trop Med Int Health 2007; 12: 687-94.
57. Stringer JSA, Zulu I, Levy J, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia. feasibility and early outcomes. JAMA 2006; 296: 782-93.
58. Laufer MK, van Oosterhout JJG, Perez A, et al. Observational cohort study of HIV-infected African children. Ped Infect Dis J 2006; 25: 623-7.
59. HIV Paediatric Prognostic Markers Collaborative Study Group. Short-term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysis. Lancet 2003; 362: 1605-11.
60. Bong CN, Yu JKL, Chiang HC, et al. Risk factors for early mortality in children on adult fixed-dose combination antiretroviral treatment in a central hospital in Malawi. AIDS 2007; 21: 1805-10.
61. Ellis J, Molyneux EM. Experience of anti-retroviral treatment for HIV-infected children in Malawi: the 1st 12 months. Ann Trop Paediatr 2007; 27: 261-7.
62. Eley B, Davies MA, Apolles P, et al. Antiretroviral treatment for children. SA J Med 2006; 96: 988-93.
63. Taha TE, Kumwenda NI, Hoover DR, et al. Association of HIV-1 load and CD4 lymphocyte count with mortality among untreated African children over one year of age. AIDS 2000; 14: 453-9.
64. Bong CN, Chen SCC, Jong YJ, et al. Outcomes of HIV-infected children with tuberculosis who are started on antiretroviral therapy in Malawi. Int J Tuberc Lung Dis 2007; 11: 534-8.
65. Murdoch DM, Venter WDF, Van Rie A, Feldman C. Immune reconstitution inflammatory syndrome (IRIS): review of common infectious manifestations and treatment options. AIDS Res Ther 2007; 4: 9. Available online: http//www.aidsrestherapy.com/content/4/1/9 (accessed June 12, 2008).
66. French MA, Price P, Stone SF. Immune restoration disease after antiretroviral therapy. AIDS 2004; 18: 1615-28.
67. Orrell C, Bangsberg DR, Badri M, Wood R. Adherence is not a barrier to successful antiretroviral therapy in South Africa. AIDS 2003; 17: 1369-75.
68. Gibb DM, Goodall RL, Giacomet V, McGee L, Companucci A, Lyall H. Adherence to prescribed antiretroviral therapy in human immunodeficiency virus-infected children in the PENTA 5 trial. Ped Infect Dis J 2008; 22: 56-62.
69. Müller AD, Bode S, Myer L, Roux P, von Steinbüchel N. Electronic measurement of adherence to pediatric antiretroviral therapy in South Africa. Ped Infect Dis J 2008; 27: 257-62.
70. Arrivé E, Anaky MF, Wemin ML, et al. Assessment of adherence to highly active antiretroviral therapy in a cohort of African HIV-infected children in Abidjan, Côte d'Ivoire. J Acquir Immune Defic Syndr 2005; 40: 498-500.
71. van Oosterhout JJ, Bodasing N, Kumwenda JJ, et al. Evaluation of anitretroviral therapy results in a resource-poor setting in Blantyre, Malawi. Trop Med Int Health 2005; 10: 464-70.
72. Seyler C, Anglaret X, Dakoury-Dogbo N, et al. Medium-term survival, morbidity and immunovirological evolution in HIV-infected adults receiving antiretroviral therapy, Abidjan, Côte d'Ivoire. Antivir Ther 2003; 8: 385-93.
73. Ferradini L, Jeannin A, Pinoges L, et al. Scaling up of highly active antiretroviral therapy in a rural district in Malawi: an effectiveness assessment. Lancet 2006; 367: 1335-42.
74. Bikaako-Kajura W, Luyirika E, Purcell DW, et al. Disclosure of HIV status and adherence to daily drug regimens among HIV-infected children in Uganda. AIDS Behav 2006; 10: S85-S93.
75. Paediatric European Network for Treatment of AIDS. Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children. AIDS 2007; 21: 947-55.
76. Fraaij PLA, Verweel G, van Rossum AMC, et al. Sustained viral suppression and immune recovery in HIV-type 1-infected children after 4 years of highly active antiretroviral therapy. Clin Infect Dis 2005; 40: 604-8.
77. Brogly S, Williams P, Seage GR, Oleske JM, van Dyke R, McIntosh K. Antiretroviral treatment in pediatric HIV infection in the United States. From clinical trials to clinical practice. JAMA 2005; 293: 2213-20.
78. McComsey GA, Leonard E. Metabolic complications of HIV therapy in children. AIDS 2004; 18: 1753-68.
79. Verhoeff FH, Le Cessie S, Kalanda BF, Kazembe PN, Broadhead RL, Brahin BJ. Post-neonatal infant mortality in Malawi: the importance of maternal health. Ann Trop Paediatr 2004; 24: 161-9.
80. Jones SA, Sherman GG, Varga CA. Exploring socio-economic conditions and poor follow-up rates of HIV-exposed infants in Johannesburg, South Africa. AIDS Care 2005; 17: 466-70.
81. Yu JKL, Chen SCC, Wang KY, et al. True outcomes for patients on antiretroviral therapy who are lost to follow-up in Malawi. Bull World Health Organ 2007; 85: 550-4.
82. Dalal RP, MacPhail C, Mqhayi M, et al. Characteristics and outcomes of adult patient lost to follow-up at an antiretroviral treatment clinic in Johannesburg, South Africa. J Acquir Immune Defic Syndr 2008; 47: 101-7.
83. Zachariah R, Teck R, Buhendwa L, et al. Community support is associated with better antiretroviral treatment outcomes in a resource-limited rural district in Malawi. Trans Roy Soc Trop Med Hyg 2007; 101: 79-84.
84. Bedelu M, Ford N, Hilderbrand K, Reuter H. Implementing antiretroviral therapy in rural Communities: the Lusikisiki model of decentralized HIV/ AIDS care. J Infect Dis 2007; 196: S464-S468.
85. The Working Group on Antiretroviral Therapy. Guidelines for the use of antiretroviral agents in pediatric HIV infection. February 28, 2008. Available online: http://AIDSinfo.nih.gov (accessed March 13, 2008).
86. Fassinou P, Elenga N, Rouet F, et al. Highly active antiretroviral therapies among HIV-1-infected children in Abidjan, Côte d'Ivoire. AIDS 2004; 18: 1905-13.
87. Reddi A, Leeper SC, Grobler AC, et al. Preliminary outcomes of paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa. BMC Pediatrics 2007; 7: 1-13.
88. Eley B. Addressing the paediatric HIV epidemic: a perspective from the Western Cape region of South Africa. Trans Roy Soc Trop Med Hyg 2006; 100: 19-23.
89. Walker SA, Mulenga V, Ford D, et al. The impact of daily cotrimoxazole prophylaxis and antiretroviral therapy on mortality and hospital admissions in HIV-infected Zambian children. Clin Infect Dis 2007; 44: 1361-67.
90. O'Brien DP, Sauvageot D, Zachariah R, Humblet P. In resource-limited setting good early outcomes can be achieved in children using adult fixed-dose combination antiretroviral therapy. AIDS 2006; 20: 1955-60.
91. Scherpbier HJ, Bekker V, Pajkrt D, Jurriaans S, Lange JMA, Kuijpers TW. Once-daily highly active antiretroviral therapy for HIV-infected children: safety and efficacy of an efavirenz-containing regimen. Pediatrics 2007; 119: e705-715.
92. Luzuriaga K, McManus M, Mofenson L, Britto P, Graham B, Sullivan JL. A trial of three antiretroviral regimens in HIV-1-infected children. N Engl J Med 2004; 350: 2471-80.
93. European collaborative study. CD4 cell response to antiretroviral therapy in children with wertically acquired HIV infection: is it associated with age at initiation? J Infect Dis 2006; 193: 954-62.
94. Laurent C, Kouanfack C, Koulla-Shiro S, et al. Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial. Lancet 2004; 364: 29-34.
95. Lum H, Isichei C, Isichei-Wakili M, Redfield R. Expansion of HIV-1 screening and anti-retroviral treatment programs in a resource-poor setting: results from a faith-based organization in Jos, Plateau State, Nigeria. Afr Health Sci 2007; 7: 93-100.
96. Etard JF, Ndiaye I, Thierry-Mieg M, et al. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS 2006; 20: 1181-9.
97. Bekker LG, Myer L, Orrell C, Lawn S, Wood R. Rapid scale-up of a community-base HIV treatment service. Programme perfromance over 3 consecutive years in Gugulethu. SA J Med 2006; 96: 315-20.
98. Sow PS, Otieno LF, Bissagnene E, et al. Implementation of an antiretroviral access program for HIV-1-infected individuals in resource-limited settings. J Acquir Immune Defic Syndr 2007; 44: 262-7.